Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) is now available.
JCR Pharmaceuticals reported a significant decline in financial performance for the nine months ended December 31, 2024, with a 23.2% drop in net sales and a transition to operating and ordinary losses compared to the previous year. The company’s comprehensive income also fell sharply, impacting shareholders’ equity and reflecting challenges within the company’s operational and strategic initiatives. Despite these results, the company maintains its dividend forecast, indicating efforts to uphold shareholder returns amidst financial adjustments.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a company listed on the Tokyo Stock Exchange, operating in the pharmaceutical industry. The company is known for developing and supplying pharmaceutical products, with a focus on innovative treatments that address unmet medical needs, particularly in rare and genetic diseases.
YTD Price Performance: -6.10%
Average Trading Volume: 369,071
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: Yen70.54B
For an in-depth examination of 4552 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue